Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human von Willebrand factor concentrate
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
A high-purity, plasma-derived human von Willebrand factor (VWF) concentrate investigated for the treatment of von Willebrand disease (VWD). Developed and studied in Phase I clinical trials sponsored by the National Center for Research Resources (NCRR) and the National Institutes of Health (NIH), this product was specifically designed to evaluate the pharmacokinetics and physiological effects of VWF replacement in isolation from exogenous Factor VIII. The concentrate functions by replacing deficient or dysfunctional VWF, which is essential for platelet adhesion to the vascular subendothelium at sites of injury and for the stabilization of endogenous Factor VIII in the circulation. By providing a purified source of VWF, the therapy aims to correct bleeding time and restore normal hemostatic function in patients with various subtypes of VWD.
- Other names
- von Willebrand factorhuman von Willebrand factor concentrateVWF concentrate
02
Targets
F8 (Coagulation Factor VIIIa)GP9 (Platelet glycoprotein ib-ix-v complex)ADAMTS13 (A disintegrin and metalloproteinase with thrombospondin motifs 13)COL (Collagen type XXI alpha 1 chain)
Beyond the preview
Go deeper on human von Willebrand factor concentrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human von Willebrand factor concentrate.